Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body

Executive Summary

Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.

You may also be interested in...



Alnylam's Amvuttra Tests Faster HTA In England, Wins Praise in Germany For Full Assessment

Alnylam has opted to submit its orphan drug Amvuttra for a full benefit assessment in Germany, rather than an abbreviated process that requires no comparative data. In England, the drug was recommended following a pilot for designing a new and faster approach to health technology appraisals.

Germany’s New Government Will Maintain Price Freeze And Slash Free Pricing Period

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups

The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel